Top Ranked Income Stocks to Buy for January 20th
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 20th:
Moelis & Company (MC): This provider of strategic and financial advisory services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 51% over the last 60 days.
Moelis & Company Price and Consensus
Moelis & Company price-consensus-chart | Moelis & Company Quote
This Zacks Rank #1 (Strong Buy) company has a dividend yield of 2.78%, compared with the industry average of 0.00%. Its five-year average dividend yield is 4.35%.
Moelis & Company Dividend Yield (TTM)
Moelis & Company dividend-yield-ttm | Moelis & Company Quote
Norbord Inc. (OSB): This manufacturer of wood-based panels, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days.
Norbord Inc. Price and Consensus
Norbord Inc. price-consensus-chart | Norbord Inc. Quote
This Zacks Rank #1 company has a dividend yield of 4.59%, compared with the industry average of 0.41%. Its five-year average dividend yield is 5.4%.
Norbord Inc. Dividend Yield (TTM)
Norbord Inc. dividend-yield-ttm | Norbord Inc. Quote
Rio Tinto Group (RIO): This company that engages in finding, mining, and processing mineral resources has witnessed the Zacks Consensus Estimate for its current year earnings increasing 47.3% over the last 60 days.
Rio Tinto PLC Price and Consensus
Rio Tinto PLC price-consensus-chart | Rio Tinto PLC Quote
This Zacks Rank #1 company has a dividend yield of 3.80%, compared with the industry average of 0.00%. Its five-year average dividend yield is 6.29%.
Rio Tinto PLC Dividend Yield (TTM)
Rio Tinto PLC dividend-yield-ttm | Rio Tinto PLC Quote
See the full list of top ranked stocks here.
Find more top income stocks with some of our great premium screens.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Rio Tinto PLC (RIO) : Free Stock Analysis Report
Norbord Inc. (OSB) : Free Stock Analysis Report
Moelis & Company (MC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
